SEE FAR CBT Intervention for Adults With PTSD
A Clinical Study Evaluating the Effects of a SEE FAR CBT Intervention on Psychological Outcomes in Adults With Posttraumatic Stress Disorder.
1 other identifier
interventional
60
1 country
1
Brief Summary
This single-arm clinical intervention study evaluates a 12-session SEE FAR CBT intervention for adults aged 18 years and older with posttraumatic stress disorder (PTSD). SEE FAR CBT is a trauma-focused cognitive-behavioral treatment approach. Participants will complete self-report psychological questionnaires at three time points: baseline, after completion of the intervention, and at a 3-month follow-up. The study aims to examine changes in PTSD symptoms and related psychological outcomes over the course of treatment and follow-up.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jul 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 1, 2026
CompletedStudy Start
First participant enrolled
July 1, 2026
CompletedFirst Posted
Study publicly available on registry
July 22, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
March 1, 2028
July 22, 2026
June 1, 2026
1.4 years
July 1, 2026
July 17, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Change in PTSD symptoms
PTSD Checklist for DSM-5 (PCL-5). PTSD symptoms will be assessed using the PCL-5. Total scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity. Change in PCL-5 total score will be examined from baseline to post-intervention, from baseline to 3-month follow-up, and from post-intervention to 3-month follow-up.
Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention
Change in anxiety symptoms
Generalized Anxiety Disorder-7 (GAD-7). Anxiety symptoms will be assessed using the GAD-7. Total scores range from 0 to 21, with higher scores indicating greater anxiety symptom severity. Change in GAD-7 total score will be examined from baseline to post-intervention, from baseline to 3-month follow-up, and from post-intervention to 3-month follow-up.
Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention
Secondary Outcomes (5)
Change in depressive symptoms
Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention
Change in perceived stress
Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention
Change in resilience
Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention
Change in somatic symptoms
Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention
Change in trauma-related use of imagination and coping
Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention
Study Arms (1)
SEE FAR CBT Intervention
EXPERIMENTALParticipants in this single-arm study will receive 12 therapeutic sessions of SEE FAR CBT for PTSD, delivered approximately once weekly.
Interventions
SEE FAR CBT is a trauma-focused cognitive-behavioral treatment approach. Participants will receive 12 therapeutic sessions delivered approximately once weekly as a structured psychological intervention for PTSD.
Eligibility Criteria
You may qualify if:
- Participants must meet all of the following criteria:
- Age 18 years or older
- PTSD symptoms, defined as a PCL-5 score of 30 or above
- Able to provide informed consent
You may not qualify if:
- Participants will be excluded if they meet any of the following criteria:
- Pregnancy at the time of enrollment, due to the potential influence of pregnancy and childbirth during the treatment or follow-up period on psychological outcomes.
- Currently receiving psychotherapy of any type that began less than 3 months prior to enrolment.
- Initiation of psychiatric medication less than 3 months prior to enrolment.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Community Stress Prevention Center
Kiryat Shmona, Israel
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Meital Mashash, PhD
Community Stress Prevention Center
- PRINCIPAL INVESTIGATOR
Sivan Raz, PhD
Tel Hai College
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 1, 2026
First Posted
July 22, 2026
Study Start
July 1, 2026
Primary Completion (Estimated)
December 1, 2027
Study Completion (Estimated)
March 1, 2028
Last Updated
July 22, 2026
Record last verified: 2026-06
Data Sharing
- IPD Sharing
- Will not share
Individual participant data will not be shared due to the sensitive clinical nature of the data and participant privacy considerations.